Cytorex Biosciences Inc.’s current therapeutic focus is brain cancer pathology. Preclinical studies in in-vitro and in-vivo models, in glioblastoma multiforme – GBM brain cancer cells, have shown that Cytoreg® ionic therapeutic technology has high efficacy by inducing apoptosis, demonstrates selectivity to inhibit the growth of only cancer cells and demonstrates low toxicity. Furthermore, by inducing a shift from the oxygen-poor environment of cancer cells to an oxygen-enriched environment, it prevents the growth of cancer cells
- The NCI (National Cancer Institute) defines GBM (Glioblastoma Multiforme) as a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma multiforme, and grade IV astrocytoma. The median survival time for patients with GBM is 15 to 16 months in people who get surgery, chemotherapy, and radiation treatment. Median means half of all patients with this tumor survive to this length of time”
- According to the American Cancer Society, in 2021, an estimated 24,530 new people will be diagnosed with brain tumors and other nervous system cancers this year, and nearly 18,600 are estimated to die. Brain tumors account for 85 to 90 percent of all primary central nervous system tumors.
- Center for Disaster Control and Prevention (CDC) published in its statistics that cancer is the number two killer behind heart disease. Last updated on May 1, 2021.
- By the year 2021, it is estimated that around 608,570 people will die of cancer (all types) and 1,898,160 new cases will be diagnosed this year. (Table 1 in “Cancer Facts and Figure 2021” by America Cancer Society)
- GBM tumors are graded from low grade (Grade I) to high grade (Grade IV). High-grade tumors have cells that are more abnormal, grow faster, and are more malignant than low-grade tumors.
“This cancer is slightly more common in men than women and among those with certain genetic syndromes. The rate of new cases of brain and other nervous system cancer was 6.4 per 100,000 men and women per year based on 2014–2018 cases, age-adjusted.”National Cancer Institute.